electroCore CEO to Join Company’s Board of Directors
Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that Chief Executive Officer (CEO), Francis R. Amato, has been elected to join the company’s Board of Directors effective immediately. Mr. Amato will also remain in his role as CEO of electroCore.
“Frank is a talented executive who has demonstrated strong business acumen and stewardship of growth as electroCore advances the company’s proprietary non-invasive vagus nerve stimulation (nVNS) therapy,” said J.P. Errico, Founder, Principal Investor and Chief Science & Strategy Officer of electroCore. “With this appointment, we are excited to expand his role and further benefit from his leadership.”
Mr. Amato, who has served as CEO since July 2016 and joined electroCore in 2012 as Chief Operating Officer (COO), has extensive commercial experience in the pharmaceutical industry. Prior to joining electroCore, Mr. Amato held the position of US Vice President, Specialty Commercial Operations Group, at Merck. Other senior positions held include Executive Director, Global Business Operations, at Schering-Plough; Business Unit Lead, Oncology for Ligand Pharmaceutical; and National Accounts Director, Specialty Managed Markets, for Pfizer.
electroCore’s Board of Directors is composed of senior executives drawn from business, pharma, medical devices and medicine. In addition to Mr. Amato, members of the Board include J.P. Errico, Founder, Principal Investor and Chief Science & Strategy Officer of electroCore; Thomas J. Errico, MD, Founder and Principal Investor; Kathryn K. Theofilos, Esquire, Founder and Principal Investor; Peter Staats, MD; Reese S. Terry, Jr.; David Rubin, Ph.D.; Trevor Moody, and Jim Tullis.
electroCore LLC is a U.S.-based neuroscience and technology company dedicated to improving patient outcomes through technological advancement and focused on developing non-invasive vagus nerve stimulation therapy for the treatment of multiple conditions in neurology, inflammation, and metabolic syndrome. The company’s initial target is the treatment of primary headaches (migraine and cluster headache) and the associated chronic co-morbidities of gastric motility, psychiatric, sleep, and pain disorders that drive disproportionately large direct and indirect costs within the healthcare system and society.
For more information, visit electrocore.com.
electroCore, the electroCore logo, and The NeuroScience Company are trademarks of electroCore LLC.